FDA approves Lilly's Mounjaro to cut cardiovascular event risk in high-risk type 2 diabetes adults

• FDA cleared Lilly’s Mounjaro to cut major cardiovascular event risk in adults with type 2 diabetes at high risk.
• Label expansion follows SURPASS-CVOT, a 13,299-patient trial comparing tirzepatide with Trulicity over a median 210.1 weeks.
• Mounjaro met non-inferiority, showing an 8% lower MACE-3 rate; hazard ratio 0.92 with 95.3% CI 0.83-1.01.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608280700PR_NEWS_USPR_____DE33618) on August 28, 2026, and is solely responsible for the information contained therein.